临床外科杂志 ›› 2025, Vol. 33 ›› Issue (11): 1165-1169.doi: 10.3969/j.issn.1005-6483.20241790

• 论著 • 上一篇    下一篇

血浆4个半LIM结构域蛋白2、肺表面活性蛋白A1和溶质载体家族31成员1对肺癌诊断及预后的预测价值

  

  1.  832008  新疆石河子 ,石河子大学第一附属医院心胸外科 
  • 收稿日期:2024-11-07 接受日期:2024-11-07 出版日期:2025-11-20 发布日期:2025-11-20
  • 通讯作者: 侯量,Email:rm7vz4@163.com
  • 基金资助:
    石河子大学第一附属医院科研项目(编号:LC2023001)

Predictive value of plasma FHL2,SFTPA1,SLC31A1 for diagnosis and prognosis of lung cance

  1. Department of Cardiothoracic Surgery,the First Affiliated Hospital of Shihezi University,Xinjiang,Shihezi 832008,China
  • Received:2024-11-07 Accepted:2024-11-07 Online:2025-11-20 Published:2025-11-20

摘要: 目的 探究血浆4个半LIM结构域蛋白2(FHL2)、肺表面活性蛋白A1(SFTPA1)、溶质载体家族31成员1(SLC31A1)对肺癌诊断及预后的预测价值。方法 2018年1月~2022年6月在诊治的96例肺癌病人为肺癌组,同期108例良性肺结节病人为良性病变组,120例体检的健康受试者为对照组。qRT-PCR检测FHL2表达量,ELISA检测SFTPA1、SLC31A1水平。ROC曲线分析FHL2、SFTPA1、SLC31A1对肺癌的诊断价值;Kaplan-Meier法进行生存分析;Cox回归分析肺癌病人预后不良的影响因素。结果 对照组、良性病变组及肺癌组FHL2、SLC31A1水平逐渐降低,SFTPA1水平逐渐升高,差异有统计学意义(P<0.05);FHL2、SFTPA1、SLC31A1联合诊断肺癌的曲线下面积(AUC)为0.940,优于各自单独诊断的AUC(P<0.05);FHL2、SFTPA1、SLC31A1表达与TNM分期、远处转移、分化程度相关(P<0.05);FHL2、SLC31A1高表达组2年累积生存率分别为92.31%、89.09%,高于低表达组累积生存率(63.64%、65.85%),SFTPA1高表达组2年累积生存率为67.39%,低于低表达组累积生存率(90.00%)(P<0.05);TNM分期、远处转移以及FHL2、SFTPA1、SLC31A1水平是肺癌病人死亡的影响因素(P<0.05)。结论 肺癌病人血浆中FHL2、SLC31A1水平降低,SFTPA1升高,三者对肺癌诊断具有一定的价值,FHL2、SLC31A1低表达、SFTPA1高表达是肺癌病人死亡的影响因素。

关键词: 肺癌, 4个半LIM结构域蛋白2, 肺表面活性蛋白A1, 溶质载体家族31成员1, 诊断, 预后

Abstract: Objective To investigate the predictive value of plasma four and a half LIM domains protein 2 (FHL2),pulmonary surfactant-associated glycoprotein A1 (SFTPA1),and solute carrier family 31 member 1 (SLC31A1) for diagnosis and prognosis of lung cancer.Methods From January 2018 to June 2022,96 lung cancer patients treated in our hospital were included as the lung cancer group.Another 108 patients with benign lung diseases and 120 healthy subjects who underwent physical examinations were regarded as the benign lesion group and control group,respectively.QRT-PCR was applied to detect the expression level of FHL2.ELISA was applied to detect SFTPA1 and SLC31A1 levels.ROC curve was applied to analyze the diagnostic value of FHL2,SFTPA1,and SLC31A1 for lung cancer.Kaplan-Meier method was applied for survival analysis.COX regression was applied to analyze the influencing factors of poor prognosis in lung cancer patients.Results The levels of FHL2 and SLC31A1 gradually decreased in the control group,benign lesion group,and lung cancer group,while the level of SFTPA1 gradually increased (P<0.05).The Area Under the Curve (AUC) of the combined diagnosis of lung cancer by was 0.940,which was better than their individual diagnoses (all P<0.05).The expression of FHL2,SFTPA1,and SLC31A1 was correlated with TNM staging,distant metastasis,and differentiation degree (P<0.05).The 2 year cumulative survival rates of FHL2 and SLC31A1 high expression groups were 92.31% and 89.09%,respectively,which were higher than those of the low expression groups (63.64% and 65.85%).The 2 year cumulative survival rate of SFTPA1 high expression group was 67.39%,which was lower than that of the low expression group (90.00%) (both P<0.05).TNM staging,distant metastasis,and levels of FHL2,SFTPA1,and SLC31A1 were influencing factors for mortality in lung cancer patients (P<0.05).Conclusion The levels of FHL2 and SLC31A1 in the plasma of lung cancer patients are decreased,while SFTPA1 is increased.These three factors have certain value for diagnosis of lung cancer.Low expression of FHL2 and SLC31A1,and high expression of SFTPA1 are influencing factors for mortality of lung cancer patients.

Key words: lung cancer, four and a half LIM domains protein 2, pulmonary surfactant-associated glycoprotein A1, solute carrier family 31 member 1, diagnosis, prognosis

[1] 国际肝胆胰协会中国分会 中华医学会外科学分会肝脏外科学组. 胆管癌诊断与治疗——外科专家共识(2025版)[J]. 临床外科杂志, 2025, 33(9): 897-915.
[2] 王心怡 韩丁培 李鹤成. 机器人辅助支气管镜在肺结节诊治中的应用进展[J]. 临床外科杂志, 2025, 33(9): 922-927.
[3] 周楚瑜 钟文昭. 非小细胞肺癌围术期治疗研究进展[J]. 临床外科杂志, 2025, 33(9): 933-937.
[4] 刘雪辉 张国超 黄宇菲 谭锋维. 非小细胞肺癌围手术期免疫治疗热点问题及研究进展[J]. 临床外科杂志, 2025, 33(9): 938-942.
[5] 王浩有 王伟 刘宏旭. 非小细胞肺癌新辅助免疫治疗的机遇与挑战[J]. 临床外科杂志, 2025, 33(9): 943-947.
[6] 杜宁彬 王居正 郭玲 胡艳正. 长链非编码RNA XIST和微小RNA-186-5p在非小细胞肺癌组织中的表达及其与病理特征的相关性[J]. 临床外科杂志, 2025, 33(9): 953-957.
[7] 杨谦 张军 马玉泉 李志国 毛诏旭. 肺腺癌组织lncRNA MALAT1、miR-181a-5p表达与JAK2/STAT3信号通路、临床病理特征及预后的关系[J]. 临床外科杂志, 2025, 33(9): 958-963.
[8] 方丽 田云霄 高庆利 牛广旭. 细胞周期蛋白B2、细胞周期蛋白E表达与肝癌病人临床病理特征及5年生存率的关系分析[J]. 临床外科杂志, 2025, 33(9): 981-984.
[9] 孙磊 杨玉亭 李朝辉. 胫骨平台伴髁间棘骨折病人术后关节功能恢复的影响因素及其预测效能研究[J]. 临床外科杂志, 2025, 33(9): 992-996.
[10] 程辉 李樊 赵波. 非插管视频辅助胸腔镜手术在非小细胞肺癌中的应用进展[J]. 临床外科杂志, 2025, 33(9): 1003-1006.
[11] 谢懿煊 李玉玮 许晨. 测压以及生物反馈在便秘诊断和治疗的应用[J]. 临床外科杂志, 2025, 33(8): 800-803.
[12] 徐瑞鑫 王浩力 张文伟 边洪春. 三维电视胸腔镜肺段切除术采用吲哚菁绿荧光反染法治疗Ⅰ期肺癌病人的疗效及安全性观察[J]. 临床外科杂志, 2025, 33(8): 822-826.
[13] 黄志刚 张兴伟 张宇 邹青旭. N-乙酰转移酶10、丝氨酸羟甲基转移酶 2、YTHN6-甲基腺苷RNA结合蛋白1在肺癌组织中的表达及与临床病理特征、预后的相关性[J]. 临床外科杂志, 2025, 33(8): 827-831.
[14] 汪俊 吕瑕智 陶玉 胡传朋. 血清微小核糖核酸-335-5p、内皮细胞特异性分子-1对食管癌病人的早期诊断及预后评估价值[J]. 临床外科杂志, 2025, 33(8): 836-840.
[15] 郝博 王霞 张婷. 血清半乳糖凝集素3结合蛋白生长分化因子-15联合对重症急性胰腺炎病人的预后价值[J]. 临床外科杂志, 2025, 33(7): 693-.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 宫念樵. 器官捐献供肾质量评估[J]. 临床外科杂志, 2016, 24(10): 729 .
[2] 黄洪锋. 关注公民逝世后器官捐献肾移植受体围手术期感染的预防与处理[J]. 临床外科杂志, 2016, 24(10): 732 .
[3] 邱江. 心脏死亡捐献供肾移植免疫抑制方案的选择[J]. 临床外科杂志, 2016, 24(10): 735 .
[4] 林俊. 原发性中枢神经系统恶性肿瘤供者在器官移植中的应用[J]. 临床外科杂志, 2016, 24(10): 737 .
[5] 昌盛. 中国心脏死亡捐献供肾器官的维护[J]. 临床外科杂志, 2016, 24(10): 744 .
[6] 杨华;李新长;龙成美;等. 公民逝世后器官捐献供肾移植临床分析[J]. 临床外科杂志, 2016, 24(10): 747 .
[7] 石宇;刘学刚 . 冠状动脉旁路移植术后短期内应用强化他汀对患者出血风险的研究[J]. 临床外科杂志, 2016, 24(10): 750 .
[8] 陈忠;王耀东;田毅峰;等. 肝胆管结石病规范化治疗的临床分析[J]. 临床外科杂志, 2016, 24(10): 753 .
[9] 齐卫鹏;王剑明;刘颜;等. 术前应用靛氰绿检测联合三维重建成像评估肝门部胆管癌肝脏储备功能[J]. 临床外科杂志, 2016, 24(10): 756 .
[10] 阿布力克木·毛拉尤甫;郑秉礼. 胰腺实性假乳头状瘤45例手术治疗分析[J]. 临床外科杂志, 2016, 24(10): 764 .